SAN DIEGO, July 23, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will webcast
its Quarterly Update Conference Call for the second quarter 2019 on
Tuesday, August 6 at 4:30 p.m. ET / 1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date, Halozyme will release financial results for the second
quarter ended June 30, 2019 following
the close of trading.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately fifteen minutes
prior to the call to register, download and install any necessary
audio software. The live call may be accessed by dialing (877)
824-0907 (domestic callers) or (647) 689-5655 (international
callers). A telephone replay will be available after the call by
dialing (800) 585-8367 (domestic callers) or (416) 621-4642
(international callers) using replay ID number 5549627.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug
pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for the treatment of
several cancers and has the potential to be used in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical and
biotechnology companies, including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its
ENHANZE® drug delivery technology. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-host-second-quarter-2019-financial-results-webcast-and-conference-call-300889559.html
SOURCE Halozyme Therapeutics, Inc.